Silicone based membranes for use in implantable glucose sensors
First Claim
Patent Images
1. A transcutaneous implantable continuous analyte sensor, comprising:
- a working electrode configured to be transcutaneously implanted; and
a membrane disposed over at least a portion of the working electrode, the membrane comprising a blend, the blend comprising a silicone-containing polymer and a hydrophilic polymer;
wherein the membrane is configured to reduce or block passage therethrough of acetaminophen, whereby when;
(1) the sensor is placed in a 2L bath filled with phosphate buffered saline, continuously stirred, brought to a temperature of 37°
C., allowed to equilibrate for 1 hour until the sensor reaches a flat line continuous baseline signal; and
(2) acetaminophen is then added to the bath to a dilution of 3.8 mg/dL and the sensor is then allowed to equilibrate over 1 hour while measurements are continuously recorded from the sensor;
the signal does not change by more than 1%.
1 Assignment
0 Petitions
Accused Products
Abstract
Membrane systems incorporating silicone polymers are described for use in implantable analyte sensors. Some layers of the membrane system may comprise a blend of a silicone polymer with a hydrophilic polymer, for example, a triblock poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) polymer. Such polymeric blends provide for both high oxygen solubility and aqueous analyte solubility.
824 Citations
16 Claims
-
1. A transcutaneous implantable continuous analyte sensor, comprising:
-
a working electrode configured to be transcutaneously implanted; and a membrane disposed over at least a portion of the working electrode, the membrane comprising a blend, the blend comprising a silicone-containing polymer and a hydrophilic polymer; wherein the membrane is configured to reduce or block passage therethrough of acetaminophen, whereby when; (1) the sensor is placed in a 2L bath filled with phosphate buffered saline, continuously stirred, brought to a temperature of 37°
C., allowed to equilibrate for 1 hour until the sensor reaches a flat line continuous baseline signal; and(2) acetaminophen is then added to the bath to a dilution of 3.8 mg/dL and the sensor is then allowed to equilibrate over 1 hour while measurements are continuously recorded from the sensor; the signal does not change by more than 1%. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A transcutaneous implantable continuous analyte sensor, comprising:
-
a working electrode configured to be transcutaneously implanted; and a membrane disposed over the working electrode, the membrane comprising; a first domain comprising a blend of a silicone-containing polymer and a hydrophilic polymer, the first domain configured to reduce permeability of acetaminophen; a second domain comprising an enzyme configured to react with an analyte; and a third domain comprising ionic components configured to reduce permeability of the third domain to an interfering species; wherein the first domain is configured to reduce or block passage therethrough of acetaminophen, whereby when; (1) the sensor is placed in a 2L bath filled with phosphate buffered saline, continuously stirred, brought to a temperature of 37°
C., allowed to equilibrate for 1 hour until the sensor reaches a flat line continuous baseline signal; and(2) acetaminophen is then added to the bath to a dilution of 3.8 mg/dL and the sensor is then allowed to equilibrate over 1 hour while measurements are continuously recorded from the sensor; the signal does not change by more than 1%. - View Dependent Claims (15, 16)
-
Specification